CRISPR Therapeutics AG — Director's Dealing 2019

Mar 7, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2019-03-05

Reporting Person: Klein Lawrence Otto (Chief Business Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-05	Stock Option (Right to Buy)	$40.87	A	45000	Acquired	2029-03-05	Common Shares (45000)	Direct

Footnotes

F1: This option was granted on March 5, 2019 with respect to 45,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 5, 2019.